Who
Edward Hurwitz
Director
Company insider
Files Form 4 as: Director and 10% owner, Dyne Therapeutics; Director, MacroGenics; Director, Applied Genetic Technologies; Director and 10% owner, Tvardi Therapeutics; Director and 10% owner, Sunesis Pharmaceuticals; 10% owner, Aegerion Pharmaceuticals; Other, TorreyPines Therapeutics.
In numbers
- Trades disclosed
- 141
- Buys
- 2
- Sells
- 6
- Bought
- $1.3M
- Sold
- $19.6M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 3 Apr 2009
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,152 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,152 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 30 May 2025filed 3 Jun 2025 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,500 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —6,500 | filing |
| 22 May 2024filed 24 May 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,133 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 20 May 2024filed 22 May 2024 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,500 at $0.00 | filing |
| 20 May 2024filed 22 May 2024 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —4,500 at $0.00 | filing |
News
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsMGNX · manilatimes.net · 15 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)MGNX · themarketsdaily.com · 14 Oct 2026Contrasting Phibro Animal Health (NASDAQ:PAHC) and Tvardi Therapeutics (NASDAQ:TVRD)TVRD · dailypolitical.com · 8 Oct 2026MacroGenics (NASDAQ:MGNX) vs. Keros Therapeutics (NASDAQ:KROS) Head to Head ReviewMGNX · tickerreport.com · 7 Oct 2026Head to Head Review: Tvardi Therapeutics (NASDAQ:TVRD) versus Astrazeneca (NYSE:AZN)TVRD · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Edward Hurwitz; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.